



FOR IMMEDIATE RELEASE

September 29, 2006

Contact: Marty Schatz
Vice President/Sales
mschatz@bpirx.com

Breckenridge Pharmaceutical has entered into an agreement to market PEG 3350 (Polyethylene Glycol for Oral Solution); generic version of Miralax®.

Boca Raton, Florida– Breckenridge announced today that it has entered into an agreement with YVR Therapeutics LLC – Irvine, California, to market Polyethylene Glycol 3350 Powder for Oral Solution.

YVR Technologies LLC received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Polyethylene Glycol for Oral Solution. Polyethylene Glycol for Oral Solution is the generic version of Braintree Laboratories' product Miralax®, an osmotic agent for the treatment of occasional constipation. Annual U.S. sales of this formulation of Polyethylene Glycol exceeds \$100 million.

Breckenridge will begin shipping the product immediately. Polyethylene Glycol for Oral Solution is available in 2 sizes 16oz (255gm) and 24oz (527gm).

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand™ and Generic prescription products in many therapeutic categories. The Breckenridge label is widely accepted in over 100 accounts; including Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets 100 products, more than 150 sku's, in most dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topicals.

For Further Information, please contact:

Breckenridge Pharmaceutical

Larry Lapila, Vice President Business Development

TEL: 860-828-8140 FAX: 860-828-8142

e-Mail: llapila@bpirx.com

Miralax® is a registered trademark of Braintree Laboratories, Inc.